Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global ...

Why olezarsen data and conference appearances matter for Ionis Pharmaceuticals stock Ionis Pharmaceuticals (IONS) is back in focus after fresh updates on its late stage pipeline, including new Phase 3 ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 ...

IONS stock advanced after partner GSK released positive Phase 3 data for bepirovirsen, showing 19% functional cure rates ...

Ionis Pharmaceuticals has revenue from commercialized medicines, but those products reached the market in the hands of biopharma industry partners. The genetic medicines company does have wholly owned ...

GSK (GSK) announced on Thursday that its antisense oligonucleotide bepirovirsen, developed with Ionis Pharma (IONS), reached the main goals in two late-stage trials for patients with chronic hepatitis ...

This is a new position for Capricorn Fund Managers Ltd, representing 3.58% of 13F reportable AUM as of September 30, 2025. Top holdings after the filing: WAY: $19.15 million (6.4% of AUM) as of ...

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -Ionis Pharmaceuticals said on Tuesday its experimental drug met the main goal of reducing abnormally high levels of the ...

Eli Lilly Earnings: Revenue Increases Reflect Global Demand for Oral Obesity Therapies ...

Q1 2026 Management View “Ionis entered 2026 with significant momentum, which continued to accelerate through the first quarter of this year,” Brett Monia (Founder, CEO & Director) said, adding that ...